Meconium aspiration syndrome (MAS) is a serious condition in newborns, associated with a poorly characterized inflammatory reaction. The aim of this study was to investigate a possible role for complement in pulmonary pathophysiology and systemic inflammation in experimental MAS. MAS was induced by instillation of meconium into the lungs of 12 hypoxic piglets. Six controls received saline under otherwise identical conditions. Hemo-and lung dynamics were recorded for 5 h. Plasma complement activation, revealed by the terminal sC5b-9 complex (TCC), and cytokines were measured by enzyme immunoassays. TCC increased substantially in MAS animals compared with controls (p Ͻ 0.0005). The increase in TCC correlated with lung dysfunction: closely with oxygenation index (r ϭ 0.51, p Ͻ 0.0001) and ventilation index (r ϭ 0.64, p Ͻ 0.0001) and inversely with lung compliance (r ϭ Ϫ0.22, p ϭ 0.05). IL-1␤ and tumor necrosis factor-␣ increased significantly in MAS animals compared with the controls (p ϭ 0.004 and 0.008, respectively). The cytokine increase occurred later than TCC and showed correlations with lung dysfunction similar to TCC. IL-10 did not discriminate between MAS animals and controls (p ϭ 0.32). Finally, the subgroup of MAS animals that died (n ϭ 5) had substantially higher TCC concentration compared with the surviving MAS animals (n ϭ 7; p Ͻ 0.0005). TCC increased substantially in MAS and was closely correlated to lung dysfunction. Complement activation preceded cytokine release, which may suggest a primary role for complement in the pathophysiology of MAS. Intrauterine passage of meconium has for centuries been interpreted as a sign of perinatal death or suppression of placental function (7). Since the 1970s, there has been a growing body of evidence suggesting detrimental effects of meconium on newborn lungs, and therapeutic suctioning of the airways to clear meconium therefore was established routinely (11, 12) . Intratracheal suction should be performed only in selective cases (13). The role of meconium per se in the pathophysiology of MAS is still debated (14) and has been questioned by Katz and Bowes (4), claiming that antenatal asphyxia leading to persistent pulmonary hypertension could cause the lung injury, leaving a minor role to direct effects mediated by meconium.
Meconium staining of amniotic fluid (MSAF) occurs frequently, reported in 5-25% of all deliveries (1-3), but most infants with MSAF are not affected (1,4 -9) . Of the minority (5%) who develop meconium aspiration syndrome (MAS), 30% are in need of respiratory support, rendering MAS the most frequent cause for the use of extracorporal membrane oxygenation in the neonatal period (10) .
Intrauterine passage of meconium has for centuries been interpreted as a sign of perinatal death or suppression of placental function (7) . Since the 1970s, there has been a growing body of evidence suggesting detrimental effects of meconium on newborn lungs, and therapeutic suctioning of the airways to clear meconium therefore was established routinely (11, 12) . Intratracheal suction should be performed only in selective cases (13) . The role of meconium per se in the pathophysiology of MAS is still debated (14) and has been questioned by Katz and Bowes (4) , claiming that antenatal asphyxia leading to persistent pulmonary hypertension could cause the lung injury, leaving a minor role to direct effects mediated by meconium.
In clinical medicine, the diversity between MSAF and MAS may be due to several meconium-related factors, such as different amounts being aspirated (15) , composition (16 -18) and consistency (19) of meconium, intrauterine effects of meconium (4, 20) , and severity and duration of accompanying asphyxia (4) . In the experimental model used in the present study (21) , most of these factors can be standardized. Still, in previous experiments using the same model with higher doses of meconium, we have observed a substantial interanimal variation in morbidity and mortality, leading us to speculate that various host factors could be related to the severity of the inflammation triggered by meconium.
Inflammation is important in the pathogenesis of MAS, but the extent of data permitting explanation for the inflammatory reactions at a molecular level are still limited. Meconium was found to increase the production of eicosanoids via phospholipase A 2 (18) , to stimulate production of tumor necrosis factor-␣ (TNF-␣) (22) , and to increase the expression of intracellular adhesion molecule-1 (23) . Furthermore, meconium may both inhibit (24) and stimulate phagocytosis (23, 24) and stimulate chemotaxis, the latter effect claimed to be due to IL-8 present in meconium (25) . Two reports on meconiuminduced oxidative burst are contradictory (24, 26) .
Complement is part of the innate immune system and plays an important role in inflammation and tissue damage in various pathophysiologic conditions (27) . We recently observed that meconium is a potent activator of the alternative complement pathway in vitro (28) . In the present study, we aimed to investigate the role of complement activation in experimental MAS, with emphasis on its relation to morbidity and its possible role in MAS-induced inflammation.
METHODS

Animals.
Norwegian Domestic race piglets, maximum 2 d old, were selected at two farms by two farmers and delivered on the day of experiment. Their weight range was 1.6 -2.3 kg (1.8 Ϯ 0.1). Exclusion criteria were weight Ͻ1200 g, Hb Ͻ5 g/dL, oxygen saturation Ͻ90% in room air, hypoxia time Ͻ30 min, or death within 30 min of reoxygenation. Two animals were excluded in accordance with the death criterion. Five of the 12 animals of the MAS group died after 30 min of reoxygenation and were included in the study. They died at the following time points: 105, 129, 168, 233, and 245 min of reoxygenation, respectively. Physiologic data for MAS and control animals are shown in Table 1 . There was no difference in physiologic markers between the two groups of animals before instillation of meconium, and the weight was equal in the two groups.
Anesthesia and surgery. Anesthesia induction was by 5% halothane in an equal mixture of air and oxygen (3 ϩ 3 L) until sleep and thereafter reduced to a maintenance level of 1-2%. The piglets were tracheotomized in supine position with infiltration anesthesia (lidocaine 10 mg/mL, maximum 7 mg/kg). Furthermore, the piglets were ventilated (Laerdal silicone resuscitation bag, infant size; Laerdal, Stavanger, Norway) through an uncuffed endotracheal tube (inner diameter 3.5 mm; Portex Ltd Hythe, Kent, UK) while boluses of pentobarbital sodium (20 mg/kg), fentanyl (50 g/kg), and pancuronium (0.4 mg/kg) were injected intravenously. For the rest of the experiment, the piglets, in the supine position, were connected to a ventilator (Dräger Babylog 8000 plus, Lübeck, Germany) except for the first 30 Meconium. Samples of meconium from 58 healthy newborns were harvested from diapers with a wooden-spatula and collected in 50-mL polypropylene centrifuge tubes (Corning Inc., Acton, MA) and kept at Ϫ20°C. The samples were thawed, pooled, and processed by a hand blender (Bosch MSM 
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4001/01, Nazarje, Slovenia) in physiologic saline until the mixture was homogeneous. The batch was then freeze-dried and irradiated to secure sterility (␥-rays, 32 kGy; Institute for Energy Technology, Kjeller, Norway). There was no bacterial growth in the batch. Finally, the preparation was reconstituted with saline to a weight concentration of 135 mg/mL and frozen in aliquots at Ϫ20°C until the day of the experiment.
Experimental model. After completion of surgery, a 30-min stabilization period, and a subsequent hypoxic period, the animals were randomized by drawing lots during hypoxia for either instillation of meconium (675 mg/kg; i.e. 5 mL/kg of a preparation that contained 135 mg/mL; n ϭ 12) or an equal volume of physiologic saline (n ϭ 6) into the lungs. Hypoxia was induced by breathing 8% oxygen in nitrogen (AGA, Oslo, Norway) and maintained until base excess was ՅϪ20 mM (Ϫ21.5 Ϯ 0.6). After instillation of meconium, the piglets were manually ventilated 30 times in ambient air with the rate 1/s with an insufflation pressure securing visually adequate chest expansion. Subsequently, they were connected to the ventilator after increasing the settings: rate from 30 to 60/min, the peak inspiratory pressure (PIP) 5 cm H 2 O beyond the preceding PIP, and the fraction of inspired oxygen (FIO 2 ) from 8 to 21%. All of these adjustments were for the first 10 min of the reoxygenation period. Later, the ventilator settings were adjusted as needed to keep oxygen saturation Ͼ85% and arterial partial pressure of carbon dioxide in the range 4 -6 kPa. Maximum settings were rate 60/min, FIO 2 0.90, and PIP 45 cm H 2 O. Lung function was monitored by the ventilator. Mean airway pressure was measured at the Y-piece, and lung volumes were calculated as a function of flow. Dynamic lung compliance (C dyn ; mL/mbar) was calculated by a computer program (Software 5.n; Drägerwerk AG, Lübeck, Germany) integrated in the ventilator. Oxygenation index (OI) was calculated according to the following formula: OI ϭ (mean airway pressure ϫ FIO 2 )/ arterial oxygen pressure ϫ 7.5. Ventilation index (VI) was calculated according to the following formula: VI ϭ (arterial partial pressure of carbon dioxide ϫ 7.5 ϫ F ϫ PIP)/1000, where F is ventilation frequency/min. Blood sampling. Blood was collected from the femoral artery on eight occasions (baseline, 20 min after start of hypoxia, and 20 min and 1, 2, 3, 4, and 5 h after start of reoxygenation) in 0.7-mL portions into EDTA tubes, immediately cooled in ice, and spun at 1500 ϫ g for 15 min at 4°C. The supernatants were immediately stored at Ϫ70°C until analyzed in batch. Arterial blood gas tensions and base excess were determined on 0.2-mL samples withdrawn from the femoral artery (Ciba-Corning Bloodgas analyser 860, Medfield, MA). The catheters in the femoral arteries were continuously flushed with heparin (6 IU/h). The Hb level was measured at the start and at the end of the experiment (CibaCorning 279 Co-oximeter). The total withdrawal (Ͻ10 mL) corresponded to Ͻ10% of the total blood volume.
Complement activation. Porcine terminal sC5b-9 complex (TCC) was quantified by an enzyme immunoassay using the MAb aE11, which cross-reacts with pig (29) as capture antibody diluted in PBS and incubated in microtiter plates (COSTAR EIA plate 3590; Corning, Inc., New York, NY) overnight (50 L/well). As standard, zymosan-activated human serum was made by incubation of 10 mg of zymosan (Sigma, St. Louis, MO) per mL of a serum pool (n ϭ 10) for 1 h at 37°C. The standard was defined to contain 1000 arbitrary units (AU)/mL and was applied as a standard curve diluted 2-fold in six steps with 2.5 AU/mL as the highest standard. The porcine plasma samples were diluted 1:4. Both standard and samples were diluted in PBS that contained 0.2% azide, 0.2% Tween 20, and 20 mM EDTA and incubated for 60 min at 4°C (50 L/well). Detection antibody was a biotinylated monoclonal anti-human C6 cross-reacting with pig (Quidel, San Diego, CA), diluted in PBS that contained 0.2% Tween 20, and incubated for 60 min at 37°C (50 L/well). Streptavidinhorseradish peroxidase (RPN1231V; Amersham Biosciences Europe GmbH, Freiburg, Germany), diluted 1:400, was then added and incubated for 60 min in 37°C (50 L/well). Finally, substrate solution was added (100 L/well): 0.003% H 2 O 2 in 0.33 mM of 2,2 azino-di(3-ethyl)-benzthiazoline sulfonate (Roche Diagnostics GmbH, Mannheim, Germany) in 0.1 M of Na-acetate buffer (pH 4.0), incubated at room temperature for 15 min before stop solution (2 N of H 2 SO 4 ) was added (100 L/well). Between each incubation, the plates were washed thrice with PBS that contained 0.1% Tween 20. OD was read at 405 nm using 490 nm as reference (MRX microplate reader; Dynex Technologies, Denkendorf, Germany).
Cytokines and soluble adhesion molecules. Commercially available enzyme immunoassays were performed according to the instructions from the manufacturer for the following markers: IL-1␤ (R&D Systems, Oxford, UK), TNF-␣ (R&D Systems), IL-10 (Bio Source/Med Probe, Camarillo, CA), IL-8 (Bio Source/Med Probe), sTNF-R (Bender/AH Diagnostics, Vienna, Austria), ␥-interferon (Bio Source/Med Probe), sVCAM-1 (Bender/AH Diagnostics), sP-selectin (Bender/AH Diagnostics), and sVE-cadherin (Bender/AH Diagnostics). Only IL-1␤, TNF-␣, and IL-10 showed detectable levels in the piglet plasma samples and are discussed further. The remaining markers were undetectable either because of lack of sensitivity of the assay (many of which were human assays indicated to have some cross-reactivity to pig) or because they were not synthesized within the observation period.
Statistics. Data are shown as mean values and SEM. Delta values were used to eliminate differences between animals at baseline, and in these cases, the data are presented as percentage change from baseline. Variables that did not show normal distribution were log transformed. ANOVAs were used to compare groups (Bonferroni correction was chosen as post hoc test). This statistical method accommodates missing data (e.g. death of piglets during the observation time). Pearson correlation coefficients were estimated to model the linear relationship between variables. Rejection probability in hypothesis testing was set to 5%.
Ethics. The experimental protocol was approved by The Norwegian Animal Experimental Board.
RESULTS
Pulmonary Pathophysiology
Lung function evaluated by OI, VI, and lung compliance deteriorated substantially in MAS animals compared with the 812 controls (p Ͻ 0.0005 for all; Fig. 1). OI (Fig. 1, top) increased in MAS animals from 1.5 Ϯ 0.1 (mean Ϯ SEM) to 9.8 Ϯ 1.2 (mean Ϯ SEM for all time points after instillation of meconium) and in the controls from 1.5 Ϯ 0.1 to 2.1 Ϯ 0.1. VI (Fig.  1, middle) (Fig. 1, bottom) decreased in MAS animals from 2.2 Ϯ 0.1 to 1.2 Ϯ 0.04 and in the controls from 2.2 Ϯ 0.2 to 1.8 Ϯ 0.1. There was no statistically significant difference in tidal volumes between MAS animals (13.3 Ϯ 0.4 mL/kg; mean Ϯ SEM for all time points after instillation of meconium) and controls (13.8 Ϯ 0.25 mL/kg; p ϭ 0.65).
Complement Activation
Complement activation measured as TCC was significantly higher in MAS animals compared with the controls (p Ͻ 0.0005; Fig. 2, top) . TCC increased in MAS animals by 82 Ϯ 34% (mean Ϯ SEM for all time points after instillation of meconium) compared with a decrease in the controls (Ϫ37 Ϯ 0.1%); the latter was consistent with the hemodilution observed in all animals. TCC correlated closely with lung dysfunction: positively with OI (r ϭ 0.51; p Ͻ 0.0001; Fig. 3, top) and VI (r ϭ 0.64; p Ͻ 0.0001; Fig. 3 , middle) and negatively with lung compliance (r ϭ Ϫ0.22; p ϭ 0.05; Fig. 3, bottom) .
Cytokines
IL-1␤ increased in MAS animals from 18.0 Ϯ 1.9 to 101.5 Ϯ 30.0 pg/mL (mean Ϯ SEM for all time points after instil- 
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COMPLEMENT IN EXPERIMENTAL MAS lation of meconium), whereas no change was observed in the controls (23.5 Ϯ 7.3 to 21.7 Ϯ 2.9 pg/mL; p ϭ 0.004 MAS versus controls). IL-1␤ correlated closely with lung dysfunction: positively with OI (r ϭ 0.75; p Ͻ 0.0001; Fig. 4, top) and VI (r ϭ 0.75; p Ͻ 0.0001; Fig. 4 , middle) and negatively with lung compliance (r ϭ Ϫ0.53; p Ͻ 0.0001; Fig. 4, bottom) . IL-1␤ correlated closely with TCC 3 h after instillation of meconium (r ϭ 0.69, p ϭ 0.004).
TNF-␣ increased in MAS animals by 72 Ϯ 10% (mean Ϯ SEM for all time points after instillation of meconium) compared with 34 Ϯ 16% in the controls (p ϭ 0.008 MAS versus controls). TNF-␣ correlated closely with lung dysfunction: positively with OI (r ϭ 0.44; p ϭ 0,004; Fig. 5, top) and VI (r ϭ 0.55; p ϭ 0.0001; Fig. 5 , middle) and negatively with lung compliance (r ϭ Ϫ0.59; p Ͻ 0.0001; Fig. 5, bottom) . IL-10 increased in MAS animals from 1.5 Ϯ 0.1 to 8.8 Ϯ 4.1 pg/mL (mean Ϯ SEM for all time points after instillation of meconium) and from 2.0 Ϯ 0.6 to 3.8 Ϯ 0.8 pg/mL in controls (p ϭ 0.32 MAS versus controls).
Subgroups of Dead and Surviving MAS Animals
Pathophysiology. Five of the 12 MAS animals died during the observation period, whereas all controls survived. OI increased substantially more from 1.5 Ϯ 0.04 to 18.8 Ϯ 2.4 in the 
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subgroup of MAS animals that died compared with surviving MAS animals (1.6 Ϯ 0.09 to 5.9 Ϯ 0.8; p Ͻ 0.0005; Fig. 6,  top) . Similar significant differences were seen for VI and lung compliance between MAS animals that died and those that survived (data not shown).
Complement activation. Notably, a most extensive difference in TCC increase was observed between MAS animals with fatal outcome (265 Ϯ 90%) compared with survivors with MAS (Ϫ5.9 Ϯ 0.1%), with no overlap between TCC values in the two groups (p Ͻ 0.0005; Fig. 6, bottom) .
Cytokines. MAS animals with fatal outcome had a significantly higher increase in IL-1␤ (16.1 Ϯ 1.2 to 181.8 Ϯ 72.6 pg/mL) compared with survivors with MAS (17.7 Ϯ 0.9 to 55.6 Ϯ 8.9 pg/mL; p ϭ 0.006). TNF-␣ increased by 55 Ϯ 17% in MAS animals with fatal outcome and by 83 Ϯ 13% in surviving MAS animals, without any significant difference between the groups.
DISCUSSION
In previous experimental MAS, we have observed a substantial interanimal variation in morbidity and mortality, leading us to speculate that various host factors could be related to the severity of the inflammation triggered by meconium. In the present study, we found that meconium activated complement measured by TCC in piglets. Complement activation was substantially more pronounced in MAS animals compared with control animals, which received saline instillation instead of meconium. Furthermore, complement activation correlated closely to deterioration of lung function as measured by OI, VI, and lung compliance. IL-1␤ displayed a similar pattern as TCC but with some time latency. These data suggest that complement activation is an early and important event in the patho- . Subgroup analysis of mortality. The MAS group was divided into survivors (n ϭ 7) and nonsurvivors (n ϭ 5) and compared with respect to OI (top) and TCC (bottom). The control group (n ϭ 6) is shown to the left for comparison. The differences in OI and TCC was highly significant between the two MAS subgroups (p Ͻ 0.0005).
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COMPLEMENT IN EXPERIMENTAL MAS physiology of MAS, followed by other inflammatory reactions, such as release of cytokines.
As part of the innate immune system, complement is important in inflammation (27) . Activation of the complement cascade induces formation of inflammatory mediators such as the anaphylatoxin C5a, which stimulates inflammatory cells to produce cytokines, arachidonic acid metabolites, and reactive oxygen metabolites. However, various inflammatory mediators may induce complement activation; thus, a complex mutual interaction between complement and other arms of the inflammatory network occurs. In vitro, meconium may directly increase activity of phospholipase A 2 (18) , which catalyze formation of eicosanoids. Release of eicosanoids probably may reinforce the complement-induced induction of proinflammatory arachidonic acids. Similar mechanisms may be operative for oxygen radicals and cytokines as meconium stimulates macrophage production of TNF-␣ (22) and superoxide anion (23) .
As a preformed protein cascade, the complement system, in contrast to cytokines that need to be synthesized, is activated without latency, e.g. by exposure to foreign material, physical trauma, and ischemia (30) . This raises the possibility that complement might be activated as a result of procedures related to anesthesia, surgery, and hypoxia-induced stress in this model. The absence of complement activation in the control animals, however, rules out this possibility because these animals were treated exactly in the same manner as the MAS animals, except for instillation of meconium. Furthermore, no differences were observed in weight or physiologic markers between the groups before instillation of meconium and saline, respectively. Ventilatory support may cause inflammatory lung injury as a result of volutrauma, barotrauma, or oxygen toxicity (31) . In our study, however, there was no statistically significant difference in tidal volumes between MAS animals and controls. Despite relatively high tidal volumes, no increase in TCC or IL-1␤ was found in the control animals, indicating that meconium per se induced the inflammatory reaction, consistent with the in vitro observation that meconium is a potent activator of complement (28) . It cannot be excluded, however, that meconium-induced lung dysfunction with surfactant inactivation, local acidosis, and hypoxia may enhance the meconium-induced complement activation.
It is commonly held that lung inflammation is essential in the pathogenesis of MAS, but the documentation thereof is still limited, and most of the studies have been performed in vitro. No previous studies have documented a relation between complement activation and severity of experimental MAS. We recently documented, however, that human meconium is a potent activator of the alternative complement pathway in human adult and cord serum (28) . The present study lends further support to the hypothesis that meconium-induced complement activation may be of importance in the development of clinical MAS.
In vivo infiltration of neutrophils has been shown in experimental MAS in humans and piglets (1, 32) . Favorable effects of glucocorticoids have been documented in lungs 6 h after instillation of meconium (33, 34) . Increased neutrophil counts and chemotactic activity have been shown in tracheal aspirates from piglets 12 h after instillation of meconium (35) . Recently, we found an increase in the potent chemotactic factor IL-8 in tracheal aspirates within 8 h after instillation of meconium in hypoxic piglets (36) . Along with IL-8, the complement activation product C5a is one of the most potent chemotactic factors released during inflammation. We have measured complement activation by formation of TCC, the final product of the terminal pathway. Formation of TCC is initiated by splitting of C5 into C5a and C5b. Thus, C5a is formed during meconiuminduced complement activation, and it is reasonable to suggest that C5a may be important not only in accumulation of neutrophils in the lungs in MAS but also to their in situ activation.
Systemic inflammatory response syndrome is associated with procoagulant activity, complement activation, and cytokine release (37) . In previous animal experiments with established MAS, there was a tendency of blood clotting obstructing aspiration for blood sampling. We assumed that this might be due to hypercoagulability developing in the course of MAS. In the same experiments, we observed a significant rise of IL-8 in tracheal aspirate of animals with established MAS as opposed to control animals (38) . We therefore suggested a disseminated cascade activation in MAS. The present data on complement activation and cytokine release lend support to this hypothesis. Complement is suggested to play a pathogenic role in acute respiratory distress syndrome and septic shock (39) . Our data show a systemic activation of complement early after instillation of meconium, preceding the rise in IL-1␤ and TNF-␣, suggesting that complement activation may be upstream of cytokine production. The local activation of complement in the lungs is most likely immediate after meconium instillation. This local inflammatory reaction seems to disseminate and lead to a systemic inflammatory reaction in which complement may play a pivotal role in initiating the systemic inflammation in MAS, possibly as a result of leakage of meconium from the lung to the systemic circulation (40) . Of particular interest in this context was the observation of a very close correlation between the systemic complement activation reflected by plasma TCC and the mortality when subdividing the MAS group into survivors and nonsurvivors. Taken together, our data support the view that meconium per se is important for the inflammatory reaction in MAS.
CONCLUSION
This study has demonstrated complement activation and cytokine production in an experimental hypoxia-stressed piglet model of MAS. Complement activation as measured by TCC preceded the rise in cytokines. The increase in TCC correlated to deterioration in lung function as well as to mortality. Our data support the assumption that complement triggers early local and systemic inflammation in MAS and, thus, may be a possible target for future therapeutic intervention.
